Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors
Adcentrx Therapeutics announced today that China’s National Medical Products Administration (NMPA) has cleared the company’s...
Zai Lab Secures NMPA Approval for Tivdak (Tisotumab Vedotin) in Recurrent or Metastatic Cervical Cancer Based on Phase III innovaTV 301 Data
Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced today that China’s National Medical Products Administration (NMPA)...
Otsuka Pharmaceutical Secures NMPA Approval for Voyxact (Sibeprenlimab) in IgA Nephropathy Based on Pivotal Phase III VISIONARY Data
Otsuka Pharmaceutical Co., Ltd. (OTCMKTS: OTSKY) announced today that China’s National Medical Products Administration (NMPA)...
Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases
Hangzhou Highlightll Pharmaceutical Co., Ltd., a clinical-stage biopharmaceutical company founded in 2017, has filed a...
Boji Medical Raises $66 Million Through Private Placement to Expand Integrated CRO and TCM Innovation Platform
Boji Medical Technology Co., Ltd. (SHE: 300404), a leading China-based Clinical Research Organization (CRO), announced...
Pfizer Secures FDA Approval for Marstacimab Expanded Indication in Hemophilia A and B Across Pediatric and Adult Populations
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has...
MSD and Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Study of Trodelvy-KEYTRUDA Combination in First-Line NSCLC
Merck & Co., Inc. (MSD; NYSE: MRK) and Gilead Sciences, Inc. (NASDAQ: GILD) announced today...
J&J to Acquire Firefly Bio for $1 Billion, Adding Proprietary DAC Platform Targeting KRAS-Driven Tumors
Johnson & Johnson (J&J, NYSE: JNJ) announced today a definitive agreement to acquire Firefly Bio,...
Nurix and Roche Forge $2.3 Billion Global Collaboration for BTK Degrader Bexobrutideg Across Oncology, Immunology and Neurology
Nurix Therapeutics, Inc. (NASDAQ: NRIX) and Roche (SWX: ROP, OTCMKTS: RHHBY) announced today a comprehensive...
GSK to Acquire Nuvalent for $10.6 Billion, Adding Breakthrough Lung Cancer Therapies to Oncology Portfolio
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced today a definitive agreement to acquire Nuvalent, Inc. (NASDAQ:...
PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset
PegBio Co., Ltd. (HKG: 2565) announced receipt of the first milestone payment of HKD 61...
Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence
Sino Medical Sciences Technology Inc. (SHA: 688108) announced it has received marketing approval from Colombia’s...
Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in the...
Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy
Novo Nordisk A/S (NYSE: NVO) presented comprehensive Phase 3 results from the REIMAGINE 1-3 clinical...
Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population
Bayer AG (ETR: BAYN) announced positive results from a pivotal Phase III study presented at...
Novo Nordisk’s Zenagamtide (Amycretin) Delivers 1.71% A1C Reduction and 14.6% Weight Loss in Phase 2 Type 2 Diabetes Trial – Dual GLP-1/Amylin Agonist Advances to Phase 3
Novo Nordisk A/S (NYSE: NVO) presented positive Phase 2 results for zenagamtide (amycretin), its investigational...
Oricell Therapeutics Receives NMPA Clearance for World’s First GPC3-Targeted CAR-T Therapy in Advanced Liver Cancer – Ori-C101 Enters Confirmatory Phase II
Oricell Therapeutics Co., Ltd. announced it has received clearance from China’s National Medical Products Administration...
Boehringer Ingelheim’s Survodutide Dual Agonist Achieves 34% Visceral Fat Reduction and 60% MASLD Resolution in Phase III ADA 2026 Data
Boehringer Ingelheim announced positive results from two global Phase III trials of survodutide (BI 456906),...
Eli Lilly’s Retatrutide Delivers Unprecedented 28.3% Weight Loss and Resolves Multiple Obesity Comorbidities in Phase III TRIUMPH-1 and TRANSCEND-T2D-1 Trials
Eli Lilly and Company (NYSE: LLY) announced additional positive results from pivotal Phase III trials...
Eli Lilly’s Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages – Addresses Critical Gap in Women’s Metabolic Health
Eli Lilly and Company (NYSE: LLY) announced groundbreaking results from the ATTAIN-1 and ATTAIN-2 clinical...